5/9/2025

Q1 2025 Royalty Pharma PLC Earnings Call

Source: Yahoo

5/8/2025

Biogen Inc. stock outperforms competitors on strong trading day

Source: MarketWatch

5/8/2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Sarepta Therapeutics (NASDAQ:SRPT).

Source: Yahoo

5/7/2025

Biogen (NasdaqGS:BIIB) appointed multiple co-lead underwriters for two fixed-income offerings totaling over $1 billion, showcasing its efforts to bolster financial offerings. This move, coupled with Biogen's recent earnings announcement, which reported a decline in net income and sales but an increase in revenue, did not align with the generally stable market performance over the same period. While these developments reflect Biogen's current financial strategies and performance, they could...

Source: Yahoo

5/6/2025

Biogen Inc. stock underperforms Tuesday when compared to competitors

Source: MarketWatch

5/6/2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

Source: Yahoo

5/5/2025

Biogen Inc. stock underperforms Monday when compared to competitors

Source: MarketWatch

5/5/2025

Positive Lexeo Therapeutics, Inc. interim data from SUNRISE-FA study highlights LX2006's potential for Friedreich's Ataxia. Click for upcoming LXEO catalysts.

Source: SeekingAlpha

5/3/2025

Biogen ( NASDAQ:BIIB ) First Quarter 2025 Results Key Financial Results Revenue: US$2.43b (up 6.1% from 1Q 2024). Net...

Source: Yahoo

5/2/2025

Biogen (BIIB) seems to be emerging as a "leaner" and "less risky" company, RBC Capital Markets said

Source: Yahoo

5/2/2025

Biogen Inc (BIIB) reports a 6% revenue increase driven by new product launches, despite facing competitive pressures in its MS franchise.

Source: Yahoo

5/2/2025

Q1 2025 Biogen Inc Earnings Call

Source: Yahoo

5/1/2025

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

Source: Yahoo

5/1/2025

Biogen (NasdaqGS:BIIB) reported a mixed financial performance with Q1 2025 earnings illustrating a decline in net income and EPS compared to the prior year, while revenue saw an increase. This week's share price move of 1.31% likely mirrored broader market trends, as major indexes rose with investor confidence buoyed by strong earnings reports from technology firms. The mixed results from Biogen would have added complexity to its performance amid a positive market backdrop, but not diverge...

Source: Yahoo

5/1/2025

Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.

Source: Yahoo

5/1/2025

Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Source: Yahoo

5/1/2025

Biogen stock traded sideways Thursday after the company beat first-quarter expectations, including strong sales for two newcomer drugs.

Source: Yahoo

5/1/2025

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share was 1% above analysts’ consensus estimates.

Source: Yahoo

5/1/2025

Biogen (BIIB) delivered earnings and revenue surprises of -7.36% and 8.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

5/1/2025

Biogen Inc. (NASDAQ:BIIB) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsTim Power - Head, Investor RelationsChris Viehbacher -...

Source: SeekingAlpha